Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Heska Corp (HSKA) and Cytosorbents Corp (CTSO).
Heska Corp (HSKA)
B.Riley FBR analyst Kara Anderson maintained a Hold rating on Heska Corp today and set a price target of $93. The company’s shares closed yesterday at $100.87.
Anderson observed:
“PT) reported 3Q18 results that, excluding one-time charges, were in line with or better than consensus. Heska reported $31.0 million in revenue, $3.5 million in non-GAAP operating income, and non-GAAP EPS of $0.43 which compares to consensus’ $31.1 million, $3.6 million, and $0.34, respectively.”
According to TipRanks.com, Anderson is a 4-star analyst with an average return of 5.5% and a 46.2% success rate. Anderson covers the Services sector, focusing on stocks such as Weight Watchers International, Spark Networks Plc, and PCM Inc.
Heska Corp has an analyst consensus of Moderate Buy, with a price target consensus of $115.67.
See today’s analyst top recommended stocks >>
Cytosorbents Corp (CTSO)
In a report released today, Andrew D’silva from B.Riley FBR maintained a Buy rating on Cytosorbents Corp, with a price target of $16.50. The company’s shares closed yesterday at $9.65.
D’silva observed:
“CytoSorbents Corporation (CTSO) reported 3Q18 results and held a corresponding conference call at 4:45PM ET. The company posted a top-line/adj. EPS/ adj. EBITDA of $5.7M/($0.09)/($2.3)M. As previewed, this is the first time the company’s consolidated sales decline sequentially since 1Q15. As a result, shares could face pressure. We are aggressive buyers on significant dips and believe 4Q18/2019 should rebound and show significant momentum. Meanwhile, we/consensus were modeling a top-line/adj. EPS/adj. EBITDA of $5.5M/($0.15)/($2.9)M and $5.8M/($0.13)/($2.9)M, respectively. The top-line beat relative to our estimate was primarily due to grant income coming in higher than we modeled for.”
According to TipRanks.com, D’silva is a 4-star analyst with an average return of 14.0% and a 46.6% success rate. D’silva covers the Healthcare sector, focusing on stocks such as Cumberland Pharmaceuticals Inc., Sorrento Therapeutics, and Kindred Biosciences.
Currently, the analyst consensus on Cytosorbents Corp is a Strong Buy with an average price target of $16.50, representing a 71.0% upside. In a report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $15 price target.
.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
